New MediShield Life and Integrated Shield plans. Here is what has changed.

Increased MediShield Life premiums? That may not be the only thing that has increased. Read our article to find out what has changed for your MediShield Life and Integrated Shield plan.

iFAST Insurance Team
iFAST Insurance Team15 Apr 2025 6754 Views


Changes to MediShield Life (MSHL)

Following the recommendations from the MediShield Life council in October 2024, the MediShield Life scheme will be enhanced with the revised benefits progressively implemented. Some of these changes will be implemented with effect from 1 April 2025. This is what we know about the changes that have been implemented and the other changes that will be implemented over the next few years.


1) Premiums before subsidies will increase by as much as 35 per cent from April 2025

Our MediShield Life premiums will increase with this done in phases from April 2025 to March 2028. Premium support will also be given for 2025 and 2026 to help cushion the impact of this premium adjustment. As at time of writing, the new premiums have been implemented and will take effect for policies purchased or renewed on or after 1 April 2025.


2) Inpatient deductible will increase by up to $1,500

One of the main changes announced in October 2024 was the increase of inpatient deductible for MediShield Life. The current inpatient deductible ranges from $1,500 to $3,000 and has remained unchanged since MediShield Life was introduced in 2015. This deductible was initially implemented to sieve out smaller medical bills, keep premium increases in control and allow MediShield Life to focus on the larger bills. However, the rising medical bills has deemed this deductible insufficient at achieving its intended cause.

The MediShield Life council has recommended the inpatient deductible to increase by up to $1,500 with this increase to be done in phases over the next three years. While the first increase in inpatient deductible was initially set for April 2025, as at time of writing we have not been able to find any confirmation that the new inpatient deductible has taken effect.

(Source: MediShield Life report 2024)


3) Increase in maximum claim limits and other benefits

Apart from premium increases and the increase in deductibles, the revised MediShield Life will also offer higher benefit limits. The annual policy claim limit has been increased from $150,000 to $200,000 among other things.

We summarised a list of benefit changes between the new and old MediShield Life in the table below:

(Source: MediShield Life report 2024)


With the updates to MediShield Life, there has also been changes to Integrated Shield plans. Here are the changes:

  • Enhanced IncomeShield and IncomeShield
  • Premium revision: Premiums are revised for foreigner rates to all Enhanced IncomeShield plans, IncomeShield Plan P, IncomeShield Plan A and IncomeShield Standard Plan effectivefrom April 2025. There are no changes to the premiums of riders.

    Changes to benefit: No changes.

  • Singlife Shield
  • Premium revision: Singlife Shield and Singlife Health Plus premiums will be raised from 1 April 2025. Premiums for Singlife will now increase gradually with age instead of by broad age bands.

    Changes to benefit: There are four main changes to the benefit for Singlife Shield plans:


    Old benefit

    New benefit with effect from 1 April 2025

    Inpatient and Outpatient Cell, Tissue and Gene Therapy
    $150,000 per policy year.
    $150,000 per treatment per lifetime. Each CTGTP treatment is only claimable once under the policy.
    Cap for co-insurance treatment at non-preferred medical providers
    Capped at $12,750 per policy year.
    No cap for co-insurance treatment at non-preferred medical providers. No changes for treatments at preferred medical providers.r.
    Children benefit
    Children get free cover if conditions are met.
    Free cover removed and converted to family discount for children benefit upon policy renewal.
    No Claims Discount (NCD) for Singlife Health Plus
    15% if the total claim payout amount during the assessment period is less than or equal to S$1,000.
    20% if the total claim payout amount during the assessment period is equal to S$0.

  • Raffles Shield
  • Premium revision: No revisions made to premiums.

    Changes to benefit: No changes.



    Have a question? Speak to us about your shield plans here:


    If you have existing shield plans with Income, Raffles or Singlife, you may also be interested in:

  • A Guide to assessing your Enhanced IncomeShield plan
  • Should I downgrade my Raffles Shield plan coverage? This is what we think
  • Assess your Singlife Shield plan with this one guide




  • Available Products on FSMOne Insurance

    Term Life, Whole Life, Critical Illness, Annuity, Health, Endowment, General Insurance (Personal and Commercial)


    from AIG, Allianz, Cigna, Chubb, Etiqa Insurance, FWD Insurance, Great Eastern, Henner, Income, Manulife, MSIG, Raffles Health Insurance, Singlife, Sompo, Tokio Marine, and QBE.


    *Please check with our team if the product you want is available on FSMOne Insurance



    Information obtained from:

    https://www.cpf.gov.sg/member/healthcare-financing/medishield-life/what-medishield-life-covers-you-for

    https://isomer-user-content.by.gov.sg/3/c33f49bb-869d-4ff0-88ef-755e9602402d/medishieldlife-report-2024.pdf

    https://www.moh.gov.sg/managing-expenses/schemes-and-subsidies/medishield-life/medishield-life-premium-and-subsidy-tables

    https://www.moh.gov.sg/newsroom/government-accepts-medishield-life-council-s-recommendations-to-enhance-medishield-life-scheme---government-support-more-than-offsets-premium-increases

    https://singlife.com/content/dam/public/sg/documents/promotion/H44%20Singlife%20Shield%20TCs%20Sept%202024.pdf

    https://singlife.com/content/dam/public/sg/documents/medical-insurance/singlife-shield/singlife-shield-policy-contract-2025.pdf

    https://singlife.com/content/dam/public/sg/documents/promotion/H46%20Singlife%20Health%20Plus%20TCs%20Sept%202024.pdf

    https://singlife.com/content/dam/public/sg/documents/medical-insurance/singlife-shield/singlife-health-plus-policy-contract-2025.pdf

    Information retrieved on 3 April 2025.



    Disclaimer(s):

    All materials and content found in this article are strictly for information purposes only and should not be considered as an offer or solicitation to transact in any product. This article is not a contract of insurance.

    Insurance products are underwritten by the respective insurance partners and distributed by iFAST Financial Pte Ltd (“iFAST”). You are advised to review the specific terms, conditions and exclusions in the relevant policy contract.

    You are advised to read the key product documents, including (but not limited to) the product summary, before deciding whether the product is suitable for you. You should consider carefully if the products you are purchasing are suitable for your financial objectives, experience, risk tolerance and other personal circumstances. If you are uncertain about the suitability of a product, please seek advice from a financial adviser before making a decision to purchase the product.

    While iFAST and its third-party providers strive to provide accurate and timely information, there may be inadvertent omissions, inaccuracies, and typographical errors. Opinions expressed herein are subjected to change without notice. More information on iFAST Digital Term can be found here: https://secure.fundsupermart.com/fsmone/insurance/ifast-digital-term.

    Purchasing a life insurance policy is a long-term commitment, and early termination may involve significant costs. The surrender value, if any, may be zero or less than the total premiums paid.

    This advertisement has not been reviewed by the Monetary Authority of Singapore.

    All materials and contents found in this site are strictly for general circulation and informational purposes only and should not be considered as an offer, or solicitation, to deal in any of the funds or products found/identified in this site. While iFAST Financial Pte Ltd ("IFPL") has tried to provide accurate and timely information, there may be inadvertent delays, omissions, technical or factual inaccuracies and typographical errors. Any opinion or estimate contained in this report is made on a general basis and neither IFPL nor any of its servants or agents have given any consideration to nor have they or any of them made any investigation of the investment objective, financial situation or particular need of any user or reader, any specific person or group of persons. You should consider carefully if the products you are going to purchase are suitable for your investment objective, investment experience, risk tolerance and other personal circumstances. If you are uncertain about the suitability of the investment product, please seek advice from a financial adviser, before making a decision to purchase the investment product. Past performance is not indicative of future performance. The value of the investment products and the income from them may fall as well as rise. Opinions expressed herein are subject to change without notice. In respect of any matters arising from, or in connection with the said research analyses or research reports, recipients of the report are to contact IFPL at 10 Collyer Quay, #26-01 Ocean Financial Centre Building, Singapore 049315, or by telephone at +65 6557 2853. Where the report contains research analyses or research reports from a foreign research house and if the recipient of such research analyses or research reports is not an accredited investor, expert investor, institutional investor or an ex-accredited investor, IFPL accepts legal responsibility for the contents of such analyses or reports to such persons only to the extent as required by law. Please note that only certain security(ies) herein are available to all investors, while the rest are only available for certain persons to invest in, such as Accredited Investors (as defined in the Securities and Futures Act) or one who invests at least S$200,000 (or its equivalent currency) per transaction. To qualify as an Accredited Investor, one needs to submit a declaration form and certain relevant supporting documents, according to iFAST’s prevailing policies and procedures.

    Please read our full disclaimers on the website at ( https://secure.fundsupermart.com/fsmone/policies/328125/investment-account-terms-&-conditions).

    iFAST Financial Pte Ltd (IFPL) (registered address: 10 Collyer Quay #26-01 Ocean Financial Centre Singapore 049315, Telephone: 6557 2000) holds the Financial Advisers Licence issued by the Monetary Authority of Singapore ('MAS') to conduct regulated activities of advising on securities, marketing of collective investment schemes and arranging of any contract of insurance in respect of life policies, other than a contract of reinsurance and the Capital Markets Services Licence issued by the MAS to conduct regulated activities of dealing in securities and providing custodial services for securities. While IFPL has made every effort to ensure the independence of the report's contents, IFPL's nature of business is such that IFPL and its connected and associated entities together with their respective directors, officers and staff may be involved in providing dealing or investment-related services in the abovementioned securities, and have taken or may take positions in the securities mentioned in this report, and may also act as the principal for any buy or sell trades.